An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab; Erlotinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Roche
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 Status changed from active, no longer recruiting to recruiting.
- 06 Feb 2017 Planned number of patients changed from 21 to 17.